Si desitges distingir els teus productes, serveis o tots dos dels d'una altra empresa, és possible que necessitis una marca o nom comercial. Descobreix què són, en què consisteix el seu procediment de registri i què implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tens un nou dispositiu, producte o procediment que resolgui un problema tècnic o tingui un avantatge pràctic, existeixen diferents formis de protegir-ho a Espanya i en altres països. Descobreix com fer-ho.
La teva innovació resideix en l'estètica, l'ornamentació o l'aparença del teu producte? Protegeix-la mitjançant un disseny industrial. Descobreix quins drets confereix el registri i com realitzar la tramitació.
Els patents publicades a tot el món són una valuosa font d'informació científica, tècnica i comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Si ets emprenedor/a o una empresa i vols potenciar i millorar la rendibilitat del teu negoci protegint de forma adequada els actius intangibles de la teva organització, en aquest espai trobaràs el necessari.
193
resultados
Última actualización
01/08/2025 [06:52:00]
Resultados 75 a 100 de 193
Resumen de: WO2025155087A1
The present invention relates to a microfluidic device for preparing lipid nanoparticles that can deliver nucleic acids, and a lipid nanoparticle preparation method using same. By using the microfluidic device, lipid nanoparticles of a desired size can be prepared by adjusting the molar ratio between compositions and the Reynolds number.
Resumen de: WO2025155269A1
The invention relates to serum containing encapsulated niaouli essential oil. In the preparation of said serum, firstly niaouli essential oil is encapsulated and then the obtained micro/nanoparticles are loaded into the serum carrier system. The serum containing encapsulated niaouli essential oil, which is the subject of the invention, contains olive oil, caprylic/capric triglyceride, cyclopentasiloxane, isopropyl myristate and encapsulated niaoulii essential oil. The serum containing encapsulated niaouli essential oil is used as a new alternative treatment method for eczema treatment.
Resumen de: WO2025153095A1
A lipid composition and a preparation method therefor and the use thereof. The lipid composition comprises the following components: an ionizable lipid and an auxiliary lipid, and does not contain a component having a preventive or therapeutic effect. The lipid composition can be used for delivering nucleic acids, macromolecular substances and small molecular substances, has a good stability, can be stored at room temperature for a long time, and can be used as a carrier in multiple fields such as cell and disease treatment and prevention.
Resumen de: WO2025153098A1
A pulmonary delivery system containing an ionizable lipid, and a preparation method therefor and the use thereof, which belong to the technical field of biomedicine. The pulmonary delivery system containing an ionizable lipid comprises an ionizable lipid, an auxiliary lipid, and a bioactive substance, and does not contain polymer-lipid conjugates. The pulmonary delivery system containing an ionizable lipid can deliver the bioactive substance to the lungs. The pulmonary delivery system has the characteristics of uniform particle size and high safety, and can efficiently deliver a therapeutic agent to the lungs. Before and after atomization, the particle properties such as the particle size, particle size distribution coefficient, potential, and encapsulation efficiency remain unchanged. The pulmonary delivery system provides a safe and effective solution for the treatment of pulmonary diseases, and has broad application prospects.
Resumen de: WO2025153099A1
The use of a prefabricated carrier in the preparation of a product for in vitro delivery of a gene into immune cells and stem cells, which belongs to the technical field of biomedicine. The use of a prefabricated carrier in the preparation of a product for in vitro delivery of a gene into immune cells and stem cells comprises the step of mixing the prefabricated carrier with a nucleic acid in a solvent to obtain a composition based on the prefabricated carrier. The composition of the prefabricated carrier comprises: an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-conjugated lipid. The prefabricated carrier can be used as a carrier tool for cell and gene therapy.
Resumen de: WO2025153097A1
The use of blank lipid nanoparticles in the preparation of an in-vivo delivery product, comprising the step of mixing the blank lipid nanoparticles with a biologically active substance in a solvent to obtain a blank lipid nanoparticle-based composition. The blank lipid nanoparticles consist of an ionizable lipid, a phospholipid, a steroid or a derivative thereof, and a polyethylene glycol-lipid conjugate. According to the blank lipid nanoparticles, the dosage of the biologically active substance can be flexibly adjusted according to the requirements of a user, and the blank lipid nanoparticles can be administered via multiple routes such as intravenous injection, intramuscular injection, intraperitoneal injection, and subcutaneous injection, all of which can achieve an ideal delivery effect.
Resumen de: US2025236585A1
The present invention provides an ionizable lipid compound, which can target spleen for delivery of biological macromolecules including nucleic acid drugs or nucleic acid vaccines with high efficiency. The present invention also relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and an active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Resumen de: EP4588910A1
Provided in the present invention are long-acting low-toxicity novel cationic lipid compounds, which are compounds shown as formula (I), or N-oxides, solvates, pharmaceutically acceptable salts or stereoisomers thereof. Further provided are a composition comprising the compounds and the use thereof for the delivery of therapeutic or prophylactic agents.
Resumen de: MX2025002927A
The present disclosure relates to a method for treating cancer in a subject that is BRCA-negative and homologous repair proficient (HRP), the method comprising administering to the subject a nucleic acid vector (e.g., a plasmid) comprising a polynucleotide that encodes an interleukin-12 (IL-12) formulated with a lipopolymer (e.g., a nanoparticle). In some aspects, the method further comprises administering to the subject an anticancer agent (e.g., a chemotherapeutic agent), an antibody or antigen-binding fragment thereof that specifically binds a vascular endothelial growth factor (VEGF) (anti-VEGF antibody), an immune checkpoint inhibitor, or any combination thereof.
Resumen de: MX2025002695A
Generally, a polymer nanomaterial encapsulation system useful in the production of polymer encapsulated nanoparticles comprised of a hydrophobic nanoparticle encapsulated in the hydrophobic region of the polymer with the external hydrophilic region of the polymer ensuring water-solubility and affording a functional group which can be utilized for the production of nanoparticle conjugates. Specifically, particular embodiments include a polymer nanoparticle structure including one or more of: a quantum dot and/or a superparamagnetic iron oxide nanoparticle and/or an upconverting nanoparticle, encapsulated in polystyrene-b-polyethylene glycol amine for the production of antibody conjugates useful in the capture of cellular targets.
Resumen de: WO2024058718A1
A heart valve prosthesis with one or more drug eluting mechanisms embedded in the prosthesis during manufacture.
Resumen de: MX2025002919A
Compounds, compositions, uses, and methods for reducing cell viability of a cancer cell, or for preventing or treating cancer, are provided herein. In certain examples, methods for reducing cell viability of a cancer cell and/or for preventing or treating cancer in a subject in need thereof are provided which may include a step of treatment with a GDP-bound form of Rab1a (Rab1a<sup>GDP</sup>), one or more expressible nucleic acids encoding Rab1a<sup>GDP</sup>, or a combination thereof.
Resumen de: MX2024015894A
The present invention is directed to lipid nanoparticles using cationic cholesterol for topical delivery for nucleic acid delivery, and when administered locally, side effects caused by systemic drug delivery can be minimized and protein expression can be confined to the site of administration. In addition, the duration of protein expression at the site of administration can be increased, and thus the lipid nanoparticles can be useful in the technical field related to nucleic acid therapeutics.
Resumen de: US2024245618A1
The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
Resumen de: CN119055798A
Provided herein are methods comprising introducing a therapeutically effective amount of an adeno-associated virus (AAV) vector into the inner ear of a mammal, the AAV vector comprises a nucleotide sequence encoding the following polypeptides: (a) a polypeptide comprising an antibody heavy chain variable domain operably linked to a signal peptide and a polypeptide comprising an antibody light chain variable domain operably linked to a signal peptide; (b) a polypeptide comprising an antigen binding antibody fragment operably linked to a signal peptide; or (c) a soluble vascular endothelial growth factor receptor operably linked to the signal peptide.
Resumen de: US2024009131A1
The disclosure features novel methods of producing nucleic acid lipid nanoparticle (LNP) compositions employing a modifying agent after formation of a precursor nucleic acid lipid nanoparticle, the produced compositions thereof, and methods involving the nucleic acid lipid nanoparticles useful in the delivery of therapeutics and/or prophylactics, such as a nucleic acid, to mammalian cells or organs to, for example, to regulate polypeptide, protein, or gene expression.
Resumen de: MX2024015149A
Provided are ionizable cationic lipids and lipid nanoparticles for the delivery of nucleic acids to cells (<i>e.g</i>., immune cells), and methods of making and using such lipids and targeted lipid nanoparticles.
Resumen de: CN119173498A
The present disclosure relates to novel lipids, nanoparticles comprising such lipids and their use for delivering therapeutic agents to a subject or treating and/or preventing a disease in the subject.
Resumen de: WO2024057039A1
The present invention relates to a method of treatment wherein a composition comprising a cannabinoid and an amphiphilic carbohydrate compound such as GCPQ is administered intranasally. The method of treatment is particularly suitable for use in central nervous system disorders. The invention further relates to the composition when formulated with other components in pharmaceutical compositions for use in therapy.
Resumen de: CN120346178A
本发明涉及一种负载雷帕霉素的仿生纳米颗粒及其制备方法与应用。本发明负载雷帕霉素的仿生纳米颗粒包括负载雷帕霉素的RZ NPs和肿瘤细胞膜；所述肿瘤细胞膜包覆负载雷帕霉素的RZ NPs；所述雷帕霉素修饰于RZ NPs的孔隙中；所述RZ NPs具有ZIF8的晶体结构。本发明的负载雷帕霉素的仿生纳米颗粒的制备方法包括负载雷帕霉素的RZ NPs的制备和用肿瘤细胞膜对RZ NPs进行修饰制备RZM NPs。本发明的RZM NPs对肿瘤具有外照射增敏的能力，由于雷帕霉素对于细胞周期具有潜在的影响可能性，能够使得肿瘤细胞停滞在对外照射更敏感的阶段从而提高放疗效果。
Resumen de: CN120349253A
本发明提供了一种完全生物可降解的可电离脂质化合物，该化合物具有如下所示的结构。该化合物可与其它脂质化合物共同制备脂质纳米颗粒，对核酸药物的包封效率高，且可在生物体内完全降解，安全性较好，适合应用于核酸药物递送、核酸疫苗、核酸治疗性药物等。#imgabs0#
Resumen de: CN120346179A
本发明属于生物技术和皮克林乳液制备技术领域，具体公开了一种微流控制备并原位包载香芹酚的卵白蛋白纳米粒的方法及其稳定的皮克林乳液。本发明制备纳米粒的方法较为方便且制备的纳米粒粒径小，简单易行，重复性高，制备速度快、效率高。且本发明利用原位加热处理后的香芹酚‑卵白蛋白纳米粒(OVA‑Car NPs)作为稳定剂制备皮克林乳液，所涉及的方法简单，制备的乳液稳定性高；可用于负载及保护香芹酚和木犀草素，提高香芹酚以及木犀草素的存储稳定性，改善了两者的使用局限性，使两者在抗菌领域有了更广阔的应用前景。
Resumen de: CN120346174A
本发明公开了一种白蛋白mRNA肠溶胶囊及其应用，本发明首次提出基于LNP冻干胶囊的口服肠道递送白蛋白mRNA的创新治疗策略，诱导机体自主合成功能性白蛋白，该方案突破了传统输注疗法的局限性，同时规避了mRNA疗法的长期生物安全风险，为低蛋白血症的治疗提供了全新的治疗方案和治疗策略。
Resumen de: CN120346180A
本发明属于肠道菌群处理技术领域，具体地涉及一种基于PDA@Fe3O4纳米颗粒的肠道菌群包埋工艺及其应用，该包埋工艺是将肠道菌群制成菌泥后加入到PDA@Fe3O4纳米颗粒悬浮液中，经孵育、离心后得到PDA@Fe3O4纳米颗粒包埋后的肠道菌群菌泥。本发明包埋工艺简单易行，提升了肠道菌群在胃肠道环境中的存活率和功能性，降低了患者服用的安全隐患及风险，增强了生物相容性，可应用于开发肠道菌群移植技术及能耐胃肠液的肠道菌群功能药物中。
Nº publicación: CN120359207A 22/07/2025
Solicitante:
南京吉迈生物技术有限公司南京绿叶制药有限公司
Resumen de: WO2024131717A1
The present invention relates to the field of biological medicines, in particular to cationic lipid compounds capable of being used for nucleic acid delivery, a preparation method therefor and the use thereof. LNPs prepared from the cationic lipid compounds having novel structures have the advantages of high transfection efficiency, etc., and in particular, the LNPs are distributed only at injection sites.
BOPI
Sede Electrónica
